Merck KGaA: Millipore deal was worth it

Merck KGaA's $6 billion purchase of Massachusetts-based biotechnology equipment supplier Millipore is "worth every euro," CEO Karl-Ludwig Kley told shareholders at his company's annual general meeting today. In February, the German drugmaker swooped in with an offer for Millipore, beating out Thermo Fisher. Including debt, the deal was valued at $7.2 billion.  Story